- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04710745
Atrial Fibrillation in Relationship to Plasma Biomarkers (AFISBIO II)
The general objective of this study is to:
A. To identify novel plasmatic biomarkers associated with prevalent/incident atrial fibrillation in patients with high risk for AF and stroke.
B. To assess predictive ability of novel plasmatic biomarkers (especially apelin and miRNAs) on prevalent/incident atrial fibrillation in patients with high risk for AF and stroke.
C. To validate predictive models from previous studies based on comorbidities, age, sex, BMI, NT-proBNP, FGF-23, IGF-1 and IGFBP-1 on prevalent/incident AF in patients with high risk for AF and stroke.
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
Atrial fibrillation (AF) is the most common sustained arrhythmia, associated with an increased risk of stroke, heart failure, and mortality. Despite the high prevalence, AF may be asymptomatic and consequently unrecognized. Detection of asymptomatic AF is challenging as only a minority of the patients is diagnosed during standard examinations with a 12 - lead ECG or a 24h ECG Holter monitoring. Furthermore, prolonged ECG monitoring is costly and can be inconvenient for the patients. Documented AF causes 15% of ischemic strokes. However, approximately 25% of ischemic strokes is of an unknown etiology. It is believed that undetected asymptomatic AF is responsible for some of these strokes.
Plasmatic biomarkers might be of importance in the early diagnosis of AF. Several plasmatic biomarkers have been studied in order to find an association with AF. Cardiac biomarkers such as natriuretic peptides and high-sensitivity troponins are increased in patients with AF. A novel biomarker that is depending on left atrial stretching and ionotropic effects is apelin. In our previous research we discovered that apelin is associated with AF, negatively correlates with AF burden, but only in patients without reduced LVEF. Similarly, parameters reflecting thrombogenesis, such as Fibrinogen and fibrin D-dimer were also found to be associated with the arrhythmia. Other protein biomarkers have been studied in relation to AF incidence. Insulin-like growth factor-binding protein 1 (IGFBP-1) and Insulin-like growth factor 1 (IGF-1) have shown an association with higher risk of incident AF. Previous research also indicated Fibroblast growth factor 23 (FGF-23) to be associated with AF.
However, biomarkers, such as the inflammatory markers high-sensitivity CRP have shown conflicting results.
Finally, in the last years, circulating microRNAs emerged as a promising biomarker of AF, having important function in suppression of messenger RNA responsible for electric and structural remodeling of the left atria.
In our previous case-matched study we discovered that selected miRNAs were associated with paroxysmal AF.
Studientyp
Einschreibung (Voraussichtlich)
Kontakte und Standorte
Studienkontakt
- Name: Allan Böhm, MD, PhD, MBA, FESC
- Telefonnummer: +421 907 411 499
- E-Mail: allan.bohm@gmail.com
Studienorte
-
-
-
Bratislava, Slowakei, 813 69
- Rekrutierung
- University Hospital Bratislava - Old Town Hospital
-
Kontakt:
- Martin Čaprnda, MD, PhD
-
Hauptermittler:
- Martin Čaprnda, MD, PhD
-
Bratislava, Slowakei, 826 06
- Rekrutierung
- University Hospital Bratislava - Hospital Ruzinov
-
Kontakt:
- Ján Páleš, MD
-
Hauptermittler:
- Ján Páleš, MD
-
Bratislava, Slowakei, 833 05
- Rekrutierung
- University Hospital Bratislava - Hospital of the Academician Ladislav Dérer
-
Kontakt:
- Tereza Hlavatá, MD
-
Hauptermittler:
- Tereza Hlavatá, MD
-
Bratislava, Slowakei, 833 48
- Rekrutierung
- National Institute for Cardiovascular Diseases
-
Kontakt:
- Allan Böhm, PhD, MBA, FESC
- Telefonnummer: +421 907 411 499
- E-Mail: allan.bohm@gmail.com
-
Hauptermittler:
- Allan Böhm, PhD, MBA, FESC
-
Malacky, Slowakei
- Rekrutierung
- Hospital Malacky
-
Kontakt:
- Tomáš Uher, MD
-
Hauptermittler:
- Tomáš Uher, MD
-
Nitra, Slowakei, 950 01
- Rekrutierung
- Faculty Hospital Nitra
-
Kontakt:
- Peter Snopek, MD
-
Hauptermittler:
- Peter Snopek, MD
-
Unterermittler:
- Radovan Hurčík, MD
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
General inclusion criteria:
- AGE > 50 years
- No history of supraventricular arrhythmia
- Sinus rhythm at inclusion
- CHADSVASc score > 2 in men (> 3 in female)
- More than 3 specific criteria for inclusion
- Written informed consent is obtained before any study-related assessment is performed
Specific inclusion criteria:
- Age > 65
- Age > 75
- BMI > 30
- Heart failure with preserved LVEF (according to ESC GL for HF)
- Ischemic stroke
- Left atrial diameter > 45mm
- Chronic obstructive pulmonary disease
- Arterial hypertension
- PR interval > 200ms
- History of MI or (objective evidence of) chronic coronary syndrome
- Peripheral artery disease
- Thyroid disease
Exclusion Criteria:
- History of any supraventricular or ventricular arrhythmia (excluding premature contractions and 1st degree AV block)
- Therapy with anticoagulants at the time of inclusion
- Acute coronary syndrome less than 1 month prior to inclusion
- History of cardiac surgery
- Diabetes mellitus type 2
- Reduced LVEF (<50%)
- Acute or decompensated heart failure at the time of inclusion
- Cardiomyopathy
- Systemic inflammatory disease or acute inflammatory disease
- Active malignancy
- Alcoholism (≥ 8 drinks/week)
- Renal Disease (Dialysis/ transplant/ CrCl < 1ml/s)
- Liver disease (cirrhosis/ transaminase > 3x ULT/ bilirubin > 2x ULT)
- Severe or moderate mitral stenosis
- Pregnancy
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
---|---|
Study Group
Patients in sinus rhythm without history of AF, with high risk for ischemic stroke and AF.
CHA2DS2-VASc score > 2 (for females > 3) and with more than 3 specific criteria for inclusion.
|
Sampling of peripheral venous blood for analysis of plasma concentration of plasmatic markers (Apelin, microRNA, FGF-23, IGF-1, IGFBP-1) and routine analysis (laboratory parameters: NT-proBNP, D-dimer, Creatinine Clearance, CRP, Hs-troponin).
ECHO parameters:
Patient receives an ECG Holter for a 7-day monitoring.
A screening test for evaluating cognitive performance of patients done in the clinician's office.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Prevalence of AF
Zeitfenster: Within 14 days from Inclusion.
|
AF duration > 30s on surface ECG
|
Within 14 days from Inclusion.
|
Incidence of AF
Zeitfenster: Within 14 days from Inclusion.
|
AF duration > 30s on surface ECG
|
Within 14 days from Inclusion.
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Cardiovascular (CV) death
Zeitfenster: Day 175-205 from inclusion (Follow-up 3) - Day 1080-1110 from inclusion (Follow-up 6)
|
Event occurred or did not occur (Yes/No).
|
Day 175-205 from inclusion (Follow-up 3) - Day 1080-1110 from inclusion (Follow-up 6)
|
All cause death
Zeitfenster: Day 175-205 from inclusion (Follow-up 3) - Day 1080-1110 from inclusion (Follow-up 6)
|
Event occurred or did not occur (Yes/No).
|
Day 175-205 from inclusion (Follow-up 3) - Day 1080-1110 from inclusion (Follow-up 6)
|
CV death + nonfatal stroke + nonfatal myocardial infarction
Zeitfenster: Day 175-205 from inclusion (Follow-up 3) - Day 1080-1110 from inclusion (Follow-up 6)
|
Event occurred or did not occur (Yes/No).
|
Day 175-205 from inclusion (Follow-up 3) - Day 1080-1110 from inclusion (Follow-up 6)
|
Ischemic stroke
Zeitfenster: Day 175-205 from inclusion (Follow-up 3) - Day 1080-1110 from inclusion (Follow-up 6)
|
Event occurred or did not occur (Yes/No).
|
Day 175-205 from inclusion (Follow-up 3) - Day 1080-1110 from inclusion (Follow-up 6)
|
Cognitive decline assessed by Mini-Mental State Examination
Zeitfenster: Day 350-380 from inclusion (Follow-up 4) - Day 1080-1110 from inclusion (Follow-up 6)
|
Impairment observed and recorded or not observed and not recorded (Yes/No).
|
Day 350-380 from inclusion (Follow-up 4) - Day 1080-1110 from inclusion (Follow-up 6)
|
Heart failure
Zeitfenster: Day 175-205 from inclusion (Follow-up 3) - Day 1080-1110 from inclusion (Follow-up 6)
|
Event occurred or did not occur (Yes/No). If Yes, HF classification to be indicated based on LVEF: i. with preserved LVEF (HFpEF) ii. with mid-range LVEF (HFmrEF) iii. with reduced LVEF (HFrEF) |
Day 175-205 from inclusion (Follow-up 3) - Day 1080-1110 from inclusion (Follow-up 6)
|
Hospitalization due to CV cause
Zeitfenster: Day 175-205 from inclusion (Follow-up 3) - Day 1080-1110 from inclusion (Follow-up 6)
|
Event occurred or did not occur (Yes/No).
|
Day 175-205 from inclusion (Follow-up 3) - Day 1080-1110 from inclusion (Follow-up 6)
|
Acute coronary syndrome
Zeitfenster: Day 175-205 from inclusion (Follow-up 3) - Day 1080-1110 from inclusion (Follow-up 6)
|
Event occurred or did not occur (Yes/No). If Yes, type of ACS to be indicated: i. Unstable angina ii. NSTEMI iii. STEMI |
Day 175-205 from inclusion (Follow-up 3) - Day 1080-1110 from inclusion (Follow-up 6)
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 0012020
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Vorhofflimmern
-
IRCCS Policlinico S. MatteoUniversity of Pavia; Azienda Regionale Emergenza Urgenza (AREU)RekrutierungAußerklinischer Herzstillstand | Ventrikuläre Fibrillation anhaltendItalien
-
Biotronik SE & Co. KGAbgeschlossenVorhofflimmern | Bradykardie | Synkope | Kryptogener Schlaganfall | Tachykardie atrialItalien
-
The Hospital for Sick ChildrenLabatt Family Heart CentreRekrutierungVorhofflattern | Tachykardie, supraventrikulär | Tachykardie, AV-Knoten-Wiedereintritt | Tachykardie atrial | Tachykardie, reziprok | Tachykardie, paroxysmal | Fetaler Hydrops | Tachykardie, atriale EktopieVereinigte Staaten, Hongkong, Kanada, Niederlande, Schweden, Australien, Brasilien, Finnland, Frankreich, Russische Föderation, Spanien, Tschechien, Schweiz, Vereinigtes Königreich